Conceptional considerations for a German influenza pandemic preparedness plan.
Identifieur interne : 000541 ( Main/Exploration ); précédent : 000540; suivant : 000542Conceptional considerations for a German influenza pandemic preparedness plan.
Auteurs : R. Fock [Allemagne] ; H. Bergmann ; H. Bussmann ; G. Fell ; E-J Finke ; U. Koch ; M. Niedrig ; M. Peters ; D. Scholz ; A. WirtzSource :
- Medical microbiology and immunology [ 0300-8584 ] ; 2002.
Descripteurs français
- KwdFr :
- Allemagne (épidémiologie), Antiviraux (usage thérapeutique), Chimioprévention, Contrôle des maladies contagieuses, Flambées de maladies (), Grippe humaine (), Grippe humaine (épidémiologie), Humains, Planification en santé, Pneumonie à pneumocoques (), Vaccination, Vaccins antigrippaux, Virus de la grippe A (pathogénicité).
- MESH :
- pathogénicité : Virus de la grippe A.
- usage thérapeutique : Antiviraux.
- épidémiologie : Allemagne, Grippe humaine.
- Chimioprévention, Contrôle des maladies contagieuses, Flambées de maladies, Grippe humaine, Humains, Planification en santé, Pneumonie à pneumocoques, Vaccination, Vaccins antigrippaux.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Chemoprevention, Communicable Disease Control, Disease Outbreaks (prevention & control), Germany (epidemiology), Health Planning, Humans, Influenza A virus (pathogenicity), Influenza Vaccines, Influenza, Human (epidemiology), Influenza, Human (prevention & control), Pneumonia, Pneumococcal (prevention & control), Vaccination.
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human.
- pathogenicity : Influenza A virus.
- prevention & control : Disease Outbreaks, Influenza, Human, Pneumonia, Pneumococcal.
- Chemoprevention, Communicable Disease Control, Health Planning, Humans, Influenza Vaccines, Vaccination.
Abstract
A pandemic appearance of influenza A virus must be expected at any time. The limitations of health preserving and life-saving resources, which will inevitably be reached in the event of a pandemic, will be accompanied by ethical and possibly social conflicts, which can be lessened or resolved only through precautionary planning, clearly specified competencies and transparent decisions within a social consensus. In case of a shortage of vaccines and virostatic agents, decisions will have to be made with regard to the segment of the population that absolutely must be vaccinated. It is currently estimated that a (monovalent) vaccine developed for a new pandemic strain would only suffice for the single vaccination of approximately half of the German population after a year; only 10-14 million vaccine dosages would be available to provide basic immunization and single boosters to personnel required to maintain basic medical care and essential infrastructure after half a year. In the event of local influenza outbreaks, antiviral chemotherapeutic agents could be used to close the gap until a vaccine can become effective. Even if suitable influenza vaccines and virostatic agents are not sufficiently available at the start of a pandemic, it is still possible to at least prevent an outbreak of two of the most feared secondary infections that accompany influenza: pneumococcal pneumonia or meningitis and illnesses resulting from Haemophilus influenzae. Agreement still needs to be reached with manufacturers for guaranteeing the necessary vaccine production or ensuring that they have a sufficient stock to meet the minimum demand for antiviral agents and agents for symptomatic treatment.
DOI: 10.1007/s00430-002-0145-y
PubMed: 12458359
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Conceptional considerations for a German influenza pandemic preparedness plan.</title><author><name sortKey="Fock, R" sort="Fock, R" uniqKey="Fock R" first="R" last="Fock">R. Fock</name><affiliation wicri:level="3"><nlm:affiliation>Robert Koch Institute, Nordufer 20, 13352 Berlin, Germany. FockR@rki.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Robert Koch Institute, Nordufer 20, 13352 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Bergmann, H" sort="Bergmann, H" uniqKey="Bergmann H" first="H" last="Bergmann">H. Bergmann</name></author><author><name sortKey="Bussmann, H" sort="Bussmann, H" uniqKey="Bussmann H" first="H" last="Bussmann">H. Bussmann</name></author><author><name sortKey="Fell, G" sort="Fell, G" uniqKey="Fell G" first="G" last="Fell">G. Fell</name></author><author><name sortKey="Finke, E J" sort="Finke, E J" uniqKey="Finke E" first="E-J" last="Finke">E-J Finke</name></author><author><name sortKey="Koch, U" sort="Koch, U" uniqKey="Koch U" first="U" last="Koch">U. Koch</name></author><author><name sortKey="Niedrig, M" sort="Niedrig, M" uniqKey="Niedrig M" first="M" last="Niedrig">M. Niedrig</name></author><author><name sortKey="Peters, M" sort="Peters, M" uniqKey="Peters M" first="M" last="Peters">M. Peters</name></author><author><name sortKey="Scholz, D" sort="Scholz, D" uniqKey="Scholz D" first="D" last="Scholz">D. Scholz</name></author><author><name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12458359</idno><idno type="pmid">12458359</idno><idno type="doi">10.1007/s00430-002-0145-y</idno><idno type="wicri:Area/Main/Corpus">000556</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000556</idno><idno type="wicri:Area/Main/Curation">000556</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000556</idno><idno type="wicri:Area/Main/Exploration">000556</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Conceptional considerations for a German influenza pandemic preparedness plan.</title><author><name sortKey="Fock, R" sort="Fock, R" uniqKey="Fock R" first="R" last="Fock">R. Fock</name><affiliation wicri:level="3"><nlm:affiliation>Robert Koch Institute, Nordufer 20, 13352 Berlin, Germany. FockR@rki.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Robert Koch Institute, Nordufer 20, 13352 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Bergmann, H" sort="Bergmann, H" uniqKey="Bergmann H" first="H" last="Bergmann">H. Bergmann</name></author><author><name sortKey="Bussmann, H" sort="Bussmann, H" uniqKey="Bussmann H" first="H" last="Bussmann">H. Bussmann</name></author><author><name sortKey="Fell, G" sort="Fell, G" uniqKey="Fell G" first="G" last="Fell">G. Fell</name></author><author><name sortKey="Finke, E J" sort="Finke, E J" uniqKey="Finke E" first="E-J" last="Finke">E-J Finke</name></author><author><name sortKey="Koch, U" sort="Koch, U" uniqKey="Koch U" first="U" last="Koch">U. Koch</name></author><author><name sortKey="Niedrig, M" sort="Niedrig, M" uniqKey="Niedrig M" first="M" last="Niedrig">M. Niedrig</name></author><author><name sortKey="Peters, M" sort="Peters, M" uniqKey="Peters M" first="M" last="Peters">M. Peters</name></author><author><name sortKey="Scholz, D" sort="Scholz, D" uniqKey="Scholz D" first="D" last="Scholz">D. Scholz</name></author><author><name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name></author></analytic><series><title level="j">Medical microbiology and immunology</title><idno type="ISSN">0300-8584</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Chemoprevention</term><term>Communicable Disease Control</term><term>Disease Outbreaks (prevention & control)</term><term>Germany (epidemiology)</term><term>Health Planning</term><term>Humans</term><term>Influenza A virus (pathogenicity)</term><term>Influenza Vaccines</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Pneumonia, Pneumococcal (prevention & control)</term><term>Vaccination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (épidémiologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Chimioprévention</term><term>Contrôle des maladies contagieuses</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Planification en santé</term><term>Pneumonie à pneumocoques ()</term><term>Vaccination</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chemoprevention</term><term>Communicable Disease Control</term><term>Health Planning</term><term>Humans</term><term>Influenza Vaccines</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chimioprévention</term><term>Contrôle des maladies contagieuses</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Planification en santé</term><term>Pneumonie à pneumocoques</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A pandemic appearance of influenza A virus must be expected at any time. The limitations of health preserving and life-saving resources, which will inevitably be reached in the event of a pandemic, will be accompanied by ethical and possibly social conflicts, which can be lessened or resolved only through precautionary planning, clearly specified competencies and transparent decisions within a social consensus. In case of a shortage of vaccines and virostatic agents, decisions will have to be made with regard to the segment of the population that absolutely must be vaccinated. It is currently estimated that a (monovalent) vaccine developed for a new pandemic strain would only suffice for the single vaccination of approximately half of the German population after a year; only 10-14 million vaccine dosages would be available to provide basic immunization and single boosters to personnel required to maintain basic medical care and essential infrastructure after half a year. In the event of local influenza outbreaks, antiviral chemotherapeutic agents could be used to close the gap until a vaccine can become effective. Even if suitable influenza vaccines and virostatic agents are not sufficiently available at the start of a pandemic, it is still possible to at least prevent an outbreak of two of the most feared secondary infections that accompany influenza: pneumococcal pneumonia or meningitis and illnesses resulting from Haemophilus influenzae. Agreement still needs to be reached with manufacturers for guaranteeing the necessary vaccine production or ensuring that they have a sufficient stock to meet the minimum demand for antiviral agents and agents for symptomatic treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12458359</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2007</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0300-8584</ISSN><JournalIssue CitedMedium="Print"><Volume>191</Volume><Issue>3-4</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Medical microbiology and immunology</Title><ISOAbbreviation>Med. Microbiol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Conceptional considerations for a German influenza pandemic preparedness plan.</ArticleTitle><Pagination><MedlinePgn>191-5</MedlinePgn></Pagination><Abstract><AbstractText>A pandemic appearance of influenza A virus must be expected at any time. The limitations of health preserving and life-saving resources, which will inevitably be reached in the event of a pandemic, will be accompanied by ethical and possibly social conflicts, which can be lessened or resolved only through precautionary planning, clearly specified competencies and transparent decisions within a social consensus. In case of a shortage of vaccines and virostatic agents, decisions will have to be made with regard to the segment of the population that absolutely must be vaccinated. It is currently estimated that a (monovalent) vaccine developed for a new pandemic strain would only suffice for the single vaccination of approximately half of the German population after a year; only 10-14 million vaccine dosages would be available to provide basic immunization and single boosters to personnel required to maintain basic medical care and essential infrastructure after half a year. In the event of local influenza outbreaks, antiviral chemotherapeutic agents could be used to close the gap until a vaccine can become effective. Even if suitable influenza vaccines and virostatic agents are not sufficiently available at the start of a pandemic, it is still possible to at least prevent an outbreak of two of the most feared secondary infections that accompany influenza: pneumococcal pneumonia or meningitis and illnesses resulting from Haemophilus influenzae. Agreement still needs to be reached with manufacturers for guaranteeing the necessary vaccine production or ensuring that they have a sufficient stock to meet the minimum demand for antiviral agents and agents for symptomatic treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fock</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Robert Koch Institute, Nordufer 20, 13352 Berlin, Germany. FockR@rki.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bussmann</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fell</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Finke</LastName><ForeName>E-J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Niedrig</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wirtz</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Microbiol Immunol</MedlineTA><NlmUniqueID>0314524</NlmUniqueID><ISSNLinking>0300-8584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006285" MajorTopicYN="Y">Health Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011018" MajorTopicYN="N">Pneumonia, Pneumococcal</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>30</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>30</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12458359</ArticleId><ArticleId IdType="doi">10.1007/s00430-002-0145-y</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><noCountry><name sortKey="Bergmann, H" sort="Bergmann, H" uniqKey="Bergmann H" first="H" last="Bergmann">H. Bergmann</name><name sortKey="Bussmann, H" sort="Bussmann, H" uniqKey="Bussmann H" first="H" last="Bussmann">H. Bussmann</name><name sortKey="Fell, G" sort="Fell, G" uniqKey="Fell G" first="G" last="Fell">G. Fell</name><name sortKey="Finke, E J" sort="Finke, E J" uniqKey="Finke E" first="E-J" last="Finke">E-J Finke</name><name sortKey="Koch, U" sort="Koch, U" uniqKey="Koch U" first="U" last="Koch">U. Koch</name><name sortKey="Niedrig, M" sort="Niedrig, M" uniqKey="Niedrig M" first="M" last="Niedrig">M. Niedrig</name><name sortKey="Peters, M" sort="Peters, M" uniqKey="Peters M" first="M" last="Peters">M. Peters</name><name sortKey="Scholz, D" sort="Scholz, D" uniqKey="Scholz D" first="D" last="Scholz">D. Scholz</name><name sortKey="Wirtz, A" sort="Wirtz, A" uniqKey="Wirtz A" first="A" last="Wirtz">A. Wirtz</name></noCountry><country name="Allemagne"><region name="Berlin"><name sortKey="Fock, R" sort="Fock, R" uniqKey="Fock R" first="R" last="Fock">R. Fock</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000541 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000541 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12458359
|texte= Conceptional considerations for a German influenza pandemic preparedness plan.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12458359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |